ELEVAR CARE CONNECT
LIVE

Serial Number

98384000

Owner

Elevar Therapeutics, Inc.

Attorney

Cynthia Johnson Walden

Filing Date

Jan 31, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ELEVAR CARE CONNECT Trademark

Serial Number: 98384000

ELEVAR CARE CONNECT is a trademark filed by Elevar Therapeutics, Inc. on January 31, 2024. The trademark is classified under Class 36 (Insurance & Financial), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently pending registration.

Owner Contact Info

Elevar Therapeutics, Inc. (2 trademarks)

1 Bridge Plaza N, Suite 850
Fort Lee, NJ 07024

Entity Type: 03

Trademark Details

Filing Date

January 31, 2024

Registration Date

Not Registered

Published for Opposition

December 10, 2024

Goods & Services

Providing financial assistance for prescription costs; Providing financial information about healthcare insurance plans; Providing counseling and consulting in the field of healthcare insurance benefits; Providing healthcare insurance services, namely, benefit verification services, prior authorization support and information, billing and claim processing support, and claims appeal support

Providing a website featuring information in the field of patient advocacy; Providing patient advocate services in the field of cancer treatment; Providing personal support services for patients and families of patients, namely, emotional counseling and emotional support, help with medical forms; Consulting services, namely, conducting insurance benefits investigations for pharmaceutical and biotechnology patients

Providing a website featuring medical information; Providing a website featuring information in the fields of health, cancer treatment, cancer recovery and survival, patient assistance programs that provide pharmaceuticals to help patients to get treatment; Providing healthcare information to patients in the field of administering medications; Providing health information in the field of cancer treatment; Charitable services, namely, patient assistance programs to provide drugs free of charge to patients without prescription drug coverage, delayed prescription coverage approval, and interruption in prescription coverage; Individual medical counseling services provided to patients; Interactive medical monitoring and alert services for reminding patients of medicinal dosage and prescription refills for medical treatment purposes

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 26, 2026 EXRA
SOU EXTENSION 3 GRANTED
Jun 25, 2026 EX3G
SOU EXTENSION 3 FILED
Jun 25, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Jun 25, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 14, 2026 EXRA
SOU EXTENSION 2 GRANTED
Jan 13, 2026 EX2G
SOU EXTENSION 2 FILED
Jan 13, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 13, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 5, 2025 EXRA
SOU EXTENSION 1 GRANTED
Aug 4, 2025 EX1G
SOU EXTENSION 1 FILED
Aug 4, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 4, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 4, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 10, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 10, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 4, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 14, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 14, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 14, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 14, 2024 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 2, 2024 GNFN
FINAL REFUSAL E-MAILED
Oct 2, 2024 GNFR
FINAL REFUSAL WRITTEN
Oct 2, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 23, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 23, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 23, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 14, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 14, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 14, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 14, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 31, 2024 NWOS
NEW APPLICATION ENTERED
Jan 31, 2024 NWAP